The Primary Sclerosing Cholangitis drugs in development market research report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary Sclerosing Cholangitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued products.

GlobalData tracks 42 drugs in development for Primary Sclerosing Cholangitis by 33 companies/universities/institutes. The top development phase for Primary Sclerosing Cholangitis is preclinical with 18 drugs in that stage. The Primary Sclerosing Cholangitis pipeline has 41 drugs in development by companies and one by universities/ institutes. Some of the companies in the Primary Sclerosing Cholangitis pipeline products market are: Pliant Therapeutics, AbbVie and Qing Bile Therapeutics.

The key targets in the Primary Sclerosing Cholangitis pipeline products market include Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV), Integrin Beta 6 (ITGB6), and Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2).

The key mechanisms of action in the Primary Sclerosing Cholangitis pipeline product include Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Antagonist with five drugs in Phase II. The Primary Sclerosing Cholangitis pipeline products include eight routes of administration with the top ROA being Oral and ten key molecule types in the Primary Sclerosing Cholangitis pipeline products market including Small Molecule, and Peptide.

Primary Sclerosing Cholangitis overview

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness, and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

For a complete picture of Primary Sclerosing Cholangitis’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.